journal
MENU ▼
Read by QxMD icon Read
search

Leukemia & Lymphoma

journal
https://www.readbyqxmd.com/read/29165013/efficacy-and-safety-of-native-versus-pegylated-escherichia-coli-asparaginase-for-treatment-of-adults-with-high-risk-philadelphia-chromosome-negative-acute-lymphoblastic-leukemia
#1
Josep-Maria Ribera, Mireia Morgades, Pau Montesinos, Rodrigo Martino, Pere Barba, Beatriz Soria, Arancha Bermúdez, María-José Moreno, José González-Campos, Susana Vives, Cristina Gil, Eugenia Abella, Ramon Guàrdia, Daniel Martínez-Carballeira, Pilar Martínez-Sánchez, María-Luz Amigo, Santiago Mercadal, Alfons Serrano, Aurelio López-Martínez, Ferran Vall-Llovera, María-José Sánchez-Sánchez, María-Jesús Peñarrubia, María Calbacho, Jose-Angel Méndez, Juan Bergua, Antonia Cladera, Mar Tormo, Daniel García-Belmonte, Evarist Feliu, Juana Ciudad, Alberto Orfao
Native or pegylated (PEG) asparaginase (ASP) are commonly used in treatment of acute lymphoblastic leukemia (ALL), but have been scarcely compared in the same trial in adult patients. Native vs. PEG-ASP administered according to availability in each center were prospectively evaluated in adults with high-risk ALL. Ninety-one patients received native ASP and 35 PEG-ASP in induction. No significant differences were observed in complete remission, minimal residual disease levels after induction and after consolidation, disease-free survival, and overall survival...
November 22, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29165010/dnmt3a-co-mutation-is-required-for-flt3-itd-as-an-adverse-prognostic-indicator-in-intermediate-risk-cytogenetic-group-aml
#2
Juan Ma, Jennifer Dunlap, Aleksandra Paliga, Elie Traer, Richard Press, Lisong Shen, Guang Fan
This single institution cohort study of 132 AML patients investigated the clinical implications of co-mutations detected with a 42-gene NGS panel. In the intermediate-risk cytogenetic group, FLT3-ITD is an adverse prognostic indicator only in the presence of a DNMT3A co-mutation, regardless of NPM1 mutation status. In the absence of a concomitant DNMT3A mutation, there was no significant difference in overall survival between FLT3-ITD positive and FLT3-ITD negative patients. Furthermore, mutation analysis on post-induction specimens showed that residual FLT3-ITD and/or DNMT3A mutations were associated with a high frequency of therapy resistance or relapse in AML...
November 22, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29165008/building-upon-the-success-of-cart19-chimeric-antigen-receptor-t-cells-for-hematologic-malignancies
#3
Antonia Rotolo, Anastasios Karadimitris, Marco Ruella
Chimeric antigen receptor T cell (CART) therapy has dramatically changed the therapeutic prospects for B cell malignancies. Over the last decade CD19-redirected CART have demonstrated the ability to induce deep, long-lasting remissions and possibly cure patients with relapsing B cell neoplasms. Such impressive results with CART19 fostered efforts to expand this technology to other incurable malignancies that naturally do not express CD19, such as acute myeloid leukemia (AML), Hodgkin lymphoma (HL) and multiple myeloma (MM)...
November 22, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29164994/stat3-inhibition-as-a-therapeutic-strategy-for-leukemia
#4
Rubashruti Kanna, Gaurav Choudhary, Nandini Ramachandra, Ulrich Steidl, Amit Verma, Aditi Shastri
Leukemia is characterized by selective overgrowth of malignant hematopoietic stem cells (HSC's) that interfere with HSC differentiation. Cytoreductive chemotherapy can kill rapidly dividing cancerous cells but cannot eradicate the malignant HSC pool leading to relapses. Leukemic stem cells have several dysregulated pathways and the Janus kinases (JAKs) and signal transducer and activator of transcription (STAT) pathway are prominent among them. STAT3 is an important transcription factor that regulates cell growth, proliferation, and inhibits apoptosis...
November 22, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29164984/salvianolic-acid-a-a-novel-pi3k-akt-inhibitor-induces-cell-apoptosis-and-suppresses-tumor-growth-in-acute-myeloid-leukemia
#5
Renzhi Pei, Ting Si, Ying Lu, Jeff Xiwu Zhou, Lei Jiang
Salvianolic acid A (SAA), one of the main derivatives of Salvia miltiorrhiza, has been shown to possess anti-inflammatory and anti-thrombotic activities. Its role in inhibiting tumor growth, however, remains elusive. The aim of this study was to investigate the effect of SAA on acute myeloid leukemia (AML). Here, SAA showed a dose-dependent cell viability inhibition and apoptosis induction in AML cells. At the molecular level, SAA increased the expression of Bak and decreased the expression of Bcl-xL, following by PARP cleavage and caspase-3 activation...
November 22, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29164983/a-cluster-of-vitreoretinal-lymphoma-in-new-york-with-possible-link-to-the-chernobyl-nuclear-disaster
#6
Sanford Kempin, Paul T Finger, Robert Peter Gale, John Rescigno, Jeffrey Rubin, Walter Choi, Rebecca Fisher, Alexander Aizman, Ilona Genis, Stephen C Malamud, Roxana Moslehi
No abstract text is available yet for this article.
November 22, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29164981/successful-treatment-of-ph-all-with-hematopoietic-stem-cell-transplantation-from-the-same-hla-haploidentical-related-donor-of-previous-liver-transplantation
#7
Kensuke Sasaki, Yasuo Mori, Goichi Yoshimoto, Teppei Sakoda, Koji Kato, Kyoko Inadomi, Kenjiro Kamezaki, Katsuto Takenaka, Hiromi Iwasaki, Takahiro Maeda, Toshihiro Miyamoto, Koichi Akashi
No abstract text is available yet for this article.
November 22, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29164978/lend-a-study-to-establish-the-safety-and-efficacy-of-lenalidomide-and-dexamethasone-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia
#8
Satyen Harish Gohil, Nicola Maciocia, Pip Patrick, Thomas Roberts, Nicholas Counsell, Paul Smith, Laura Clifton-Hadley, Kate Cwynarski, Andrew Pettitt, Amit Chunilal Nathwani
No abstract text is available yet for this article.
November 22, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29164977/a-retrospective-matched-paired-analysis-comparing-bendamustine-containing-beeam-versus-beam-conditioning-regimen-results-from-a-single-center-experience
#9
Khalil Saleh, Alina Danu, Serge Koscielny, Clémence Legoupil, Sylvain Pilorge, Cristina Castilla-Llorente, David Ghez, Julien Lazarovici, Jean-Marie Michot, Nadine Khalife-Saleh, Valerie Lapierre, Kamelia Alenxandrova, Julia Arfi-Rouche, Jean-Henri Bourhis, Vincent Ribrag
The combination of carmustine, etoposide, aracytin, and melphalan(BEAM) conditioning regimen in autologous stem-cell transplantation (ASCT) is widely used in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma. It is also an option in patients with very-high risk aggressive NHL in first complete remission (CR). Recently, a phase Ib-II feasibility study using bendamustine replacing carmustine (BCNU) was reported. We report herein a safety and efficacy analysis of bendamustine-EAM (BeEAM) with a control BEAM counterpart paired cohort (1/2)...
November 22, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29164976/ibrutinib-and-idelalisib-block-immunophenotypic-changes-associated-with-the-adhesion-and-activation-of-cll-cells-in-the-tumor-microenvironment
#10
Yandong Shen, O Giles Best, Stephen P Mulligan, Richard I Christopherson
The lymph node and bone marrow microenvironments promote the survival and proliferation of CLL cells. Defining the immunophenotype of CLL cells from the tumor microenvironment may help to better understand the mechanisms of action of current therapies and identify novel drug targets. Significant changes in the levels of 25 CD antigens were identified using the DotScan™ antibody microarray following CLL-cell culture with CD40L-expressing fibroblasts. Ibrutinib or idelalisib countered the change in expression of 11 of these antigens (CD23, CD27, CD53, CD58, CD71, CD80, CD84, CD97, CD126, CD150, and FMC7), which have known roles in cell activation and adhesion...
November 22, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29164971/allogeneic-hematopoietic-cell-transplantation-for-lymphoma-baseline-and-posttransplant-prognostic-factors
#11
Sun-Hye Ko, Jung-Hee Lee, Je-Hwan Lee, Han-Seung Park, Eun-Ji Choi, Miee Seol, Young-Shin Lee, Young-Ah Kang, Mijin Jeon, Kyoo-Hyung Lee
The present study aimed to investigate baseline and posttransplant prognostic factors for allogeneic hematopoietic cell transplantation (HCT) in 61 lymphoma patients. The 5-year probabilities of overall survival (OS), non-relapse mortality (NRM), progression-free survival (PFS), and event-free survival (EFS) were 31.1%, 28.8%, 38.8%, and 23.2%, respectively. Multivariate analysis demonstrated that the International Prognostic Index risk at HCT was a significantly independent prognostic factor for OS, NRM, PFS, and EFS, and chemosensitivity was a prognostic factor for OS, NRM, and EFS...
November 22, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29164966/minimal-residual-disease-detected-by-immunoglobulin-sequencing-predicts-cll-relapse-more-effectively-than-flow-cytometry
#12
Andrew Aw, Haesook T Kim, Stacey M Fernandes, Kevin Hoang, Siddha Kasar, Malek Faham, Jennifer R Brown
No abstract text is available yet for this article.
November 22, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29164965/the-importance-of-flt3-mutational-analysis-in-acute-myeloid-leukemia
#13
Mrinal M Patnaik
Activating mutations in FMS-like tyrosine kinase 3 (FLT3), including internal tandem duplications (ITDs) and tyrosine kinase domain (TKD) mutations, are common in patients with acute myeloid leukemia (AML). FLT3-ITD is a negative prognostic factor that remains prognostically relevant even after intensive chemotherapy and/or stem cell transplant. FLT3 testing was historically viewed as being purely prognostic; however, with the advent of FLT3 inhibitors, it will likely be seen as both prognostic and predictive...
November 22, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29164964/a-mouse-model-of-disseminated-mantle-cell-lymphoma-highlights-a-lack-of-activity-of-estrogen-receptor-%C3%AE-agonists-toward-tumor-burden
#14
Simon Body, Anna Esteve-Arenys, Clara Recasens-Zorzo, Xavier Troussard, Gaël Roué, Brigitte Sola
No abstract text is available yet for this article.
November 22, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29160734/immunoparesis-and-polyclonal-immunoglobulin-recovery-after-auto-sct-for-patients-with-multiple-myeloma-treated-at-a-single-institution
#15
Victor H Jimenez-Zepeda, Peter Duggan, Paola Neri, Ahsan Chaudhry, Jason Tay, Nizar Bahlis
Immunoparesis and polyclonal immunoglobulin recovery have been recently described as common indicators of immune dysfunction in patients with multiple myeloma. In the present study, we aimed to assess the impact of immunoparesis and polyclonal immunoglobulin recovery at day-100 post autologous stem cell transplant (auto-SCT) on clinical outcomes. A total of 302 patients were included for the analysis of immunoparesis, and 197 were evaluable for polyclonal immunoglobulin recovery evaluation. Immunoparesis was observed in 93...
November 21, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29160731/combination-antiretroviral-therapy-accelerates-immune-recovery-in-patients-with-hiv-related-lymphoma-treated-with-epoch-a-comparison-within-one-prospective-trial-amc034
#16
Carlyn Rose C Tan, Stefan K Barta, Jeannette Lee, Michelle A Rudek, Joseph A Sparano, Ariela Noy
Drug-drug interactions between cART and chemotherapy may impact HIV and lymphoma control or lead to increased toxicities. No prospective comparative data informs potential harms and benefits. In AMC034, HIV-associated high-grade B-cell NHL patients received DA-EPOCH with rituximab. cART was given with EPOCH or delayed until chemotherapy completion per investigator choice. Pharmacokinetic, immunological, and treatment effects of concurrent cART were evaluated. CD4 counts dropped during EPOCH in both groups but recovered to higher than baseline 6 months post-EPOCH only in the cART group...
November 21, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29119847/myeloid-lymphoid-neoplasms-with-fgfr1-rearrangement
#17
Paolo Strati, Guilin Tang, Dzifa Y Duose, Saradhi Mallampati, Rajyalakshmi Luthra, Keyur P Patel, Mohammad Hussaini, Abu-Sayeef Mirza, Rami S Komrokji, Stephen Oh, John Mascarenhas, Vesna Najfeld, Vivek Subbiah, Hagop Kantarjian, Guillermo Garcia-Manero, Srdan Verstovsek, Naval Daver
Myeloid/lymphoid neoplasms with FGFR1 rearrangement are a rare entity. We present a multicenter experience of 17 patients with FISH-confirmed FGFR1 rearrangement. The clinical presentation at diagnosis included myeloproliferative neoplasm (MPN) in 4 (24%) patients, acute leukemia (AL) in 7 (41%), and concomitant MPN with AL in 6 (35%). The two most frequently observed cytogenetic abnormalities were t(8;13)(p11.2;q12)(partner gene ZMYM2) and t(8;22)(p11.2; q11.2)(BCR). Seventy-eight percent of tested patients had a RUNX1 mutation, of whom all had AL...
November 9, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29119842/outcomes-following-front-line-chemotherapy-in-peripheral-t-cell-lymphoma-10-year-experience-at-the-royal-marsden-and-the-christie-hospital
#18
Mary Gleeson, Clare Peckitt, David Cunningham, Adam Gibb, Eliza A Hawkes, Morgan Back, Binnaz Yasar, Kate Foley, Rebecca Lee, Joanna Dash, Hannah Johnson, Catherine O'Hara, Andrew Wotherspoon, Ayoma Attygalle, Lia Menasce, Patrick Shenjere, Mike Potter, Mark E Ethell, Claire Dearden, John Radford, Ian Chau, Kim Linton
We evaluated the outcomes for patients with peripheral T-cell lymphoma (PTCL) undergoing front-line chemotherapy at our institutions between 2002 and 2012. One hundred and fifty-six patients were eligible, comprising PTCL not otherwise specified (NOS) (n = 50, 32.0%), angioimmunoblastic T-cell lymphoma (AITL) (n = 44, 28.2%), anaplastic large-cell lymphoma (ALCL) ALK negative (n = 23, 14.7%), ALCL ALK positive (n = 16, 10.3%), and other (n = 23, 14.7%). Most patients received CHOP (66.0%) and 13...
November 9, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29115897/next-generation-sequencing-discriminates-myelodysplastic-myeloproliferative-neoplasms-from-paraneoplastic-leukemoid-reaction-in-cancer-patients-with-hyperleukocytosis
#19
Riwa Sakr, Aline Renneville, Veronique Saada, Sophie Cotteret, Jean-Edouard Martin, Nathalie Droin, Dorothée Selimoglu-Buet, Benjamin Besse, Antoine Hollebecque, Christophe Marzac, Florence Pasquier, Jean-Baptiste Micol, Stéphane De Botton, Olivier Mir, Eric Solary, Christophe Willekens
No abstract text is available yet for this article.
November 8, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29115896/drugging-dna-repair-to-target-t-all-cells
#20
Yashodhara Dasgupta, Konstantin Golovine, Margaret Nieborowska-Skorska, Li Luo, Ksenia Matlawska-Wasowska, Charles G Mullighan, Tomasz Skorski
No abstract text is available yet for this article.
November 8, 2017: Leukemia & Lymphoma
journal
journal
30440
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"